Drug Profile
Research programme: chimeric antigen receptor T cell therapeutics - Anixa Biosciences/Certainty Therapeutics
Alternative Names: Anti-FSH CER-T therapy - Anixa Biosciences/Certainty Therapeutics; Anti-FSH chimeric endocrine receptor T-cell technology (CER-T) - Anixa Biosciences/Certainty Therapeutics; Anti-FSH receptor CAR-T cell therapy - Certainty Therapeutics; Chimeric Endocrine Receptor T-cell technology (CER-T) - Anixa Biosciences/Certainty TherapeuticsLatest Information Update: 13 Jul 2023
Price :
$50
*
At a glance
- Originator Certainty Therapeutics
- Developer Anixa Biosciences
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 12 Jul 2023 Canadian Intellectual Property Office has issued for novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology
- 06 Oct 2021 Anixa Biosciences has patent protection for CAR-T cancer treatment technology in China
- 01 Oct 2021 Anixa Biosciences has patent protection for CAR-T cancer treatment technology in USA